{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:57:29Z","timestamp":1784696249952,"version":"3.55.0"},"reference-count":29,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Milbank Quarterly"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      <jats:boxed-text content-type=\"box\" position=\"anchor\">\n                        <jats:caption>\n                          <jats:title>Policy Points<\/jats:title>\n                        <\/jats:caption>\n                        <jats:p>\n                          <jats:list list-type=\"bullet\">\n                            <jats:list-item>\n                              <jats:p>States can use substance use disorder waivers to improve their program, but findings regarding the effects of these waivers on opioid use disorder medication treatment have shown mixed results.<\/jats:p>\n                            <\/jats:list-item>\n                            <jats:list-item>\n                              <jats:p>This study used a mixed\u2010methods design to identify strategies that states undertook as part of their waiver and that may have led to increases in the use of methadone or buprenorphine.<\/jats:p>\n                            <\/jats:list-item>\n                            <jats:list-item>\n                              <jats:p>For methadone, adding coverage, increasing reimbursement rates, and engaging providers and managed care organizations may be effective strategies to increase the use of this medication. In contrast, no consistent strategies were identified for buprenorphine.<\/jats:p>\n                            <\/jats:list-item>\n                          <\/jats:list>\n                        <\/jats:p>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Starting in 2015, states could apply for section 1115 substance use disorder (SUD) waivers to strengthen their continuum of care for treatment of opioid use disorder (OUD). Prior research found substantial variation in changes to medication use for OUD associated with waiver implementation. The objective of this study was to identify strategies that states undertook as part of their waivers that were associated with increases in methadone and buprenorphine treatment in eight waiver states (Indiana, Louisiana, New Hampshire, New Jersey, Pennsylvania, Virginia, Washington, and West Virginia).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this mixed\u2010methods study, we combined quantitative difference\u2010in\u2010differences analyses of 2016\u20102021 Medicaid data with qualitative analyses of states\u2019 waiver application documents (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u00a08) and interviews (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u00a023) with individuals involved in waiver implementation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>\n                      SUD waiver implementation was associated with increased use of methadone in Virginia (estimate: 15.4 percentage points [pp];\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001), Indiana (estimate: 13.2 pp;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001), West Virginia (estimate: 9.5 pp;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001), Louisiana (estimate: 7.2 pp;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001), and New Jersey (estimate: 4.2 pp;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.05). Qualitative information indicated that these states used a variety of strategies, including adding coverage, increasing reimbursement rates, and engaging providers and managed care organizations. By contrast, we observed limited or no strategies to increase the use of methadone in the other states. SUD waiver implementation was associated with increased buprenorphine prescribing in Pennsylvania (estimate: 5.2 pp;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001), Washington (estimate: 5.2 pp;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001), New Hampshire (estimate: 4.4 pp;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.01), Louisiana (estimate: 4.2 pp;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.01), and Indiana (estimate: 4.2 pp;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.01). Qualitative analyses suggested that states with and without increases in this outcome implemented similar changes (e.g., education and training activities).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Qualitative findings helped explain state\u2010level variation in methadone treatment following SUD waiver implementation but not for buprenorphine. Strategies identified in higher\u2010performing states may offer useful insights for other states aiming to expand access to methadone for OUD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1468-0009.70059","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:26:21Z","timestamp":1761657981000},"page":"319-336","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["How Did Medicaid's 1115 Substance Use Disorder Waivers Increase Medication Treatment for Opioid Use Disorder? Evidence From Eight Waiver States"],"prefix":"10.1111","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-6287","authenticated-orcid":false,"given":"STEPHAN R.","family":"LINDNER","sequence":"first","affiliation":[{"name":"Center for Health Systems Effectiveness Oregon Health &amp; Science University"},{"name":"OHSU\u2010PSU School of Public Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JENNIFER","family":"HALL","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BRYNNA","family":"MANIBUSAN","sequence":"additional","affiliation":[{"name":"Center for Health Systems Effectiveness Oregon Health &amp; Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JORDAN","family":"BYERS","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KYLE","family":"HART","sequence":"additional","affiliation":[{"name":"Center for Health Systems Effectiveness Oregon Health &amp; Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANDREA","family":"BARON","sequence":"additional","affiliation":[{"name":"Boulder Care"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DENNIS","family":"McCARTY","sequence":"additional","affiliation":[{"name":"Center for Health Systems Effectiveness Oregon Health &amp; Science University"},{"name":"OHSU\u2010PSU School of Public Health"},{"name":"School of Medicine Oregon Health &amp; Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1280-3196","authenticated-orcid":false,"given":"K. JOHN","family":"McCONNELL","sequence":"additional","affiliation":[{"name":"Center for Health Systems Effectiveness Oregon Health &amp; Science University"},{"name":"OHSU\u2010PSU School of Public Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DEBORAH J.","family":"COHEN","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"National Center for Health Statistics. U.S.overdose deaths decrease almost 27% in 2024. Centers for Disease Control and Prevention. May 14 2025. Accessed July 16 2025.https:\/\/web.archive.org\/web\/20250915224058\/https:\/\/cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2025\/20250514.htm"},{"key":"e_1_2_10_3_1","doi-asserted-by":"crossref","unstructured":"SpencerMR GarnettMF Mini\u00f1oAM.Drug overdose deaths in the United States 2002\u20132022. NCHS Data Brief No. 491. CDC Stacks. March 2024. Accessed March 13 2025.https:\/\/dx.doi.org\/10.15620\/cdc:135849","DOI":"10.15620\/cdc:135849"},{"issue":"2","key":"e_1_2_10_4_1","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick RP","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"e_1_2_10_5_1","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick R","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01369.x"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.5523"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.202000565"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.12686"},{"key":"e_1_2_10_10_1","volume-title":"The Opioid Epidemic and Medicaid's Role in Facilitating Access to Treatment","author":"Orgera K","year":"2025"},{"key":"e_1_2_10_11_1","article-title":"New service delivery opportunities for individuals with a substance use disorder","author":"Wachino V","year":"2025","journal-title":"Centers for Medicare and Medicaid Services, Department of Health and Human Services"},{"key":"e_1_2_10_12_1","unstructured":"NealeB.Strategies to address the opioid epidemic. Centers for Medicare and Medicaid Services Department of Health and Human Service. November 1 2017. SMD 17\u2010003. Accessed September 29 2025.https:\/\/www.medicaid.gov\/federal\u2010policy\u2010guidance\/downloads\/smd17003.pdf"},{"key":"e_1_2_10_13_1","unstructured":"Medicaid waiver tracker: approved and pending section 1115 waivers by state.Kaiser Family Foundation. July 15 2025. Accessed July 16 2025.https:\/\/www.kff.org\/medicaid\/issue\u2010brief\/medicaid\u2010waiver\u2010tracker\u2010approved\u2010and\u2010pending\u2010section\u20101115\u2010waivers\u2010by\u2010state\/"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2024.00461"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2023.00715"},{"key":"e_1_2_10_16_1","volume-title":"Expanding Access to Addiction Treatment Services Through Section 1115 Waivers for Substance Use Disorders: Experiences From Virginia and Maryland","author":"Cunningham P","year":"2025"},{"key":"e_1_2_10_17_1","volume-title":"Designing and Conducting Mixed Methods Research","author":"Creswell JW","year":"2017"},{"key":"e_1_2_10_18_1","volume-title":"T\u2010MSIS Analytic Files (TAF) Research Identifiable Files (RIFs) User Guide","author":"Chronic Conditions Warehouse Virtual Research Data Center","year":"2025"},{"key":"e_1_2_10_19_1","volume-title":"Identifying Beneficiaries With Full\u2010Scope, Comprehensive, and Limited Benefits in the TAF","author":"Nolan L","year":"2025"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7374"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.1574"},{"key":"e_1_2_10_22_1","unstructured":"Status of state Medicaid expansion decisions.Kaiser Family Foundation. September 12 2025. Accessed July 17 2025.https:\/\/www.kff.org\/status\u2010of\u2010state\u2010medicaid\u2010expansion\u2010decisions\/"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.7455"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2019.01656"},{"key":"e_1_2_10_25_1","unstructured":"Centers for Medicare and Medicaid Services.State waivers list. Medicaid.gov. Accessed March 13 2025.https:\/\/www.medicaid.gov\/medicaid\/section\u20101115\u2010demo\/demonstration\u2010and\u2010waiver\u2010list\/index.html"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.4324\/9780203793206"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111125"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.1757"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.3549"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.0189"}],"container-title":["The Milbank Quarterly"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1468-0009.70059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:31:47Z","timestamp":1764747107000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1468-0009.70059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":29,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/1468-0009.70059"],"URL":"https:\/\/doi.org\/10.1111\/1468-0009.70059","archive":["Portico"],"relation":{},"ISSN":["0887-378X","1468-0009"],"issn-type":[{"value":"0887-378X","type":"print"},{"value":"1468-0009","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"2025-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}